The CHEERS trial, sponsored by University Hospital Ghent, investigates the efficacy of combining SBRT with checkpoint inhibitors (Nivolumab, Pembrolizumab, Atezolizumab) in patients with advanced solid tumors. Given the increasing use of immunotherapy in oncology, this trial addresses a significant unmet need in enhancing progression-free survival (PFS) in non-small-cell lung carcinoma, urothelial carcinoma, renal cell carcinoma, melanoma, and head-and-neck carcinoma. The results could position the combination therapy favorably in a competitive landscape dominated by monotherapies, potentially leading to expanded indications and market opportunities. The trial's completion in January 2024 and subsequent publication of results will be critical for assessing the commercial viability and strategic partnerships for further development.